Patient Square Capital LP Buys New Holdings in Dianthus Therapeutics, Inc. $DNTH

Patient Square Capital LP purchased a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 125,000 shares of the company’s stock, valued at approximately $4,919,000. Dianthus Therapeutics accounts for approximately 1.3% of Patient Square Capital LP’s holdings, making the stock its 15th biggest position.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Vestal Point Capital LP boosted its holdings in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Dianthus Therapeutics by 13.6% during the third quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock worth $64,620,000 after purchasing an additional 196,117 shares during the last quarter. Alliancebernstein L.P. lifted its position in Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock valued at $21,887,000 after purchasing an additional 149,200 shares during the period. Candriam S.C.A. boosted its holdings in Dianthus Therapeutics by 25.3% in the third quarter. Candriam S.C.A. now owns 301,428 shares of the company’s stock valued at $11,861,000 after purchasing an additional 60,852 shares during the last quarter. Finally, Sio Capital Management LLC boosted its holdings in Dianthus Therapeutics by 101.8% in the second quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock valued at $4,398,000 after purchasing an additional 119,073 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Jefferies Financial Group lifted their price objective on Dianthus Therapeutics from $66.00 to $81.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Truist Financial raised their target price on Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. HC Wainwright upped their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Wedbush raised their price objective on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $67.63.

Dianthus Therapeutics Stock Down 0.3%

Shares of Dianthus Therapeutics stock opened at $49.56 on Monday. Dianthus Therapeutics, Inc. has a twelve month low of $13.36 and a twelve month high of $57.50. The business has a 50-day moving average price of $45.59 and a 200 day moving average price of $38.25. The firm has a market cap of $2.14 billion, a PE ratio of -14.24 and a beta of 1.59.

Insider Buying and Selling

In other news, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total value of $903,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 16.56% of the company’s stock.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.